Interventional Cardiology Devices Market (2025 - 2033)

Interventional Cardiology Devices Market Summary

The global interventional cardiology devices market size was estimated at USD 10.57 billion in 2024 and is projected to reach USD 19.75 billion by 2033, growing at a CAGR of 7.25% from 2025 to 2033. The market growth is driven by the rising prevalence of cardiovascular diseases, increased demand for minimally invasive procedures, and technological advancements such as drug-eluting stents and bioresorbable vascular scaffolds.

The expanding elderly population, rising healthcare spending, and improved access to cardiac care in emerging markets also contribute to market expansion. Product innovation and integration of AI and imaging in catheter-based interventions further fuel demand. The rising prevalence of cardiovascular diseases is a primary market driver. Sedentary lifestyles, poor dietary habits, and increasing rates of obesity and diabetes have led to a global surge in coronary artery disease and other cardiac conditions. This growing disease burden has increased the demand for timely and effective interventions, boosting the adoption of stents, catheters, and other interventional tools.

In October 2024, the CDC reported that heart disease continues to be the top cause of death in the U.S., responsible for more than 919,000 deaths in 2023, or roughly one-third of all fatalities. A person dies from cardiovascular disease every 34 seconds, and around 5% of adults are affected by coronary artery disease. Between 2020 and 2021, heart disease incurred a financial toll of USD 417.9 billion in healthcare costs, medications, and lost productivity.

The shift toward minimally invasive procedures is also accelerating market growth. Interventional cardiology offers lower procedural risk, shorter hospital stays, and faster recovery times than traditional surgery. These benefits have made catheter-based treatments increasingly attractive to both patients and providers, particularly in high-volume centers and aging populations where surgical risk is a concern. Reflecting this momentum, in September 2023, the Society for Cardiovascular Angiography & Interventions (SCAI) hosted the 6th Annual SCAI Interface in Interventional Cardiology in Mumbai, India, bringing together global experts to highlight innovations and best practices in catheter-based cardiac care.

Technological innovation continues to transform the landscape of interventional cardiology. Advancements such as drug-eluting stents, bioresorbable scaffolds, and AI-assisted imaging have improved procedures' precision, safety, and long-term outcomes. Companies investing in smart devices, image-guided navigation, and next-generation delivery systems are helping drive clinical adoption and market expansion. In May 2025, Cordis launched a global registry study to evaluate long-term outcomes of its SELUTION SLR drug-eluting balloon in up to 10,000 patients. The initiative includes global experts, including a Brazilian cardiologist, and aims to build robust clinical evidence for coronary interventions.

Market Concentration & Characteristics

The interventional cardiology devices industry has witnessed significant innovation, driven by robotics, artificial intelligence, and data integration advancements. Innovations in device miniaturization, precision-guided delivery systems, and AI-assisted imaging have enhanced procedural accuracy and patient outcomes. The industry is also moving toward more personalized and adaptive interventions, enabling physicians to tailor therapies based on real-time anatomical and physiological data. These innovations improve clinical performance and set new procedural safety and efficiency standards.

The market is characterized by strong merger and acquisition activity as leading medtech companies aim to expand product portfolios, integrate complementary technologies, and accelerate go-to-market strategies. These consolidations enable companies to enhance R&D capabilities, reduce time-to-market for new devices, and gain access to emerging markets. In March 2025, Boston Scientific announced its acquisition of SoniVie Ltd., a private medical device firm in Israel, for approximately USD 360 million upfront, with potential additional payments, to expand its interventional cardiology portfolio with ultrasound-based renal denervation therapy for hypertension.

Regulatory frameworks play a pivotal role in shaping product development, market entry, and post-market performance for interventional cardiology devices. Regulatory bodies such as the FDA and EMA have established rigorous clinical and manufacturing standards, especially for high-risk Class III devices. Recent shifts toward expedited review pathways for breakthrough devices and harmonized international standards support faster innovation. However, compliance with technical documentation, quality systems, and real-world evidence requirements remains critical for sustained market presence.

Manufacturers are expanding their product portfolios through continuous upgrades and introducing next-generation interventional tools. Innovations include improved stent platforms, next-gen drug delivery systems, robotic-assisted catheterization labs, and enhanced guidewire technologies. This focus on iterative improvements aims to address unmet clinical needs such as complex lesion management, reduced restenosis rates, and improved patient recovery times. Companies are also investing in platform-based ecosystems that integrate diagnostics, navigation, and therapeutic capabilities.

Global market leaders are strategically entering new geographic markets to capitalize on growing demand for advanced cardiac care, particularly in Asia-Pacific, Latin America, and the Middle East. Factors such as rising incidence of coronary artery disease, improving healthcare infrastructure, and supportive reimbursement policies are driving regional adoption. Companies leverage local partnerships, regulatory familiarity, and tailored product offerings to penetrate underserved markets and strengthen global distribution networks. In April 2022, New York-Presbyterian Hudson Valley Hospital announced the launch of an Interventional Cardiology Program.

Product Insights

By product, coronary stents dominated the market and accounted for the largest share of 49.78% in 2024. This dominance is driven by the high prevalence of coronary artery disease, widespread use of stents in percutaneous coronary interventions, and continued advancements in stent technology, including drug-eluting and bioresorbable stents. The segment's growth is further supported by increasing procedure volumes, expanding clinical indications, and improved long-term outcomes associated with newer generation stent platforms. In May 2023, Shockwave Medical launched its enhanced Shockwave C2+ Coronary IVL Catheter internationally for complex calcified coronary lesions. The company also began enrolling patients in EMPOWER CAD, the first all-female IVL study in interventional cardiology.

The accessory devices segment is anticipated to witness the fastest growth during the forecast period, driven by the increasing complexity of interventional procedures and the growing need for supportive tools that enhance procedural safety and efficiency. These devices, including guidewires, catheters, introducers, and embolic protection systems, are critical in optimizing device delivery and improving clinical outcomes. Advancements in material science and device design and rising adoption of image-guided and robotic-assisted interventions are further propelling demand within this segment. In October 2024, APT Medical launched its MDR-certified Anyreach PTCA Guidewire at EuroCTO 2024 in Istanbul, enhancing its PCI product portfolio. The guidewire was featured in a live complex CTO case, demonstrating strong performance in retrograde navigation for interventional cardiology.

Regional Insights

North America dominated the interventional cardiology devices market with a revenue share of 45.06% in 2024, owing to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of innovative technologies. Strong reimbursement frameworks, a high volume of interventional procedures, and the presence of leading market players further support regional growth. In July 2024, Cook Medical relaunched its Slip-Cath hydrophilic angiographic catheter in the U.S. and Canada after a product recall in 2016. The re-engineered device supports vascular imaging and interventions, including in cardiology. It features Beacon Tip technology and a hydrophilic coating for enhanced visibility and performance.

U.S. Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in the U.S. dominated the North America region in 2024. The growth is driven by a high burden of cardiovascular diseases, widespread availability of advanced treatment options, and robust investment in research and development. A well-established reimbursement system, high procedure volumes, and the presence of key industry players contribute to the country’s strong market position. In January 2025, the American Heart Association revealed that cardiovascular disease continued to be the top cause of death in the U.S., driven by rising rates of obesity, high blood pressure, and diabetes. With over 941,000 deaths in 2022, surpassing cancer and accidents, it underscored the pressing need for better prevention strategies and expanded access to heart care.

Canada interventional cardiology devices market is anticipated to register the fastest growth rate during the forecast period, supported by rising healthcare expenditure, increasing awareness of minimally invasive cardiac procedures, and expanding access to advanced cardiovascular care. Government initiatives aimed at improving healthcare infrastructure and growing demand for early diagnosis and treatment of heart diseases are driving adoption. In July 2022, the Public Health Agency of Canada reported that heart disease remains the second leading cause of death in Canada. Around 2.6 million Canadian adults were living with the condition, with 14 deaths every hour among those diagnosed. Men are twice as likely to experience heart attacks and are typically diagnosed a decade earlier than women.

Europe Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in Europe is anticipated to grow significantly during the forecast period, due to the rising incidence of cardiovascular diseases, increasing adoption of minimally invasive procedures, and strong presence of established medical device manufacturers. Supportive government policies, a growing geriatric population, and expanding use of advanced imaging and navigation technologies in catheter-based interventions contribute to regional growth. In August 2022, Medtronic announced that it had received the European CE Mark approval for its Onyx Frontier Drug-Eluting Stent (DES). Also, Onyx Frontier had received U.S. FDA approval in May 2022. This DES significantly improves the company’s previous generation Resolute Onyx DES family.

Germany interventional cardiology devices market is anticipated to register a considerable growth rate over the forecast period, driven by a high volume of cardiac procedures, strong clinical infrastructure, and continued investment in healthcare technology. The country’s emphasis on precision medicine and integration of digital tools in interventional cardiology is also enhancing procedural outcomes and driving market demand. In September 2024, Mentice AB and the German Society of Interventional Cardiology (AGIK) formed a three-year strategic partnership to enhance interventional cardiology training in Germany.

The interventional cardiology devices market in the UK is anticipated to grow considerably during the forecast period. The growth is attributable to the rising prevalence of coronary artery disease, increasing adoption of minimally invasive treatments, and supportive government initiatives to improve cardiovascular care. Strategic collaborations between healthcare providers and medtech companies also foster innovation and accelerate the introduction of advanced interventional solutions. In 2024, the British Heart Foundation reported that there were 68,078 deaths in the UK due to coronary heart disease. The NHS’s focus on cost-effective treatments and the availability of advanced stent technologies like drug-eluting stents help improve patient outcomes.

Asia Pacific Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in Asia Pacific is expected to register the fastest growth rate over the forecast period. This is attributed to a rising burden of cardiovascular diseases, growing healthcare infrastructure, increasing adoption of advanced medical technologies, and expanding access to cardiac care in emerging economies. Rising healthcare expenditure, favorable government policies, and a surge in medical tourism further support regional market growth. A January 2024 study in Nature Communications introduced a drug-free stent coating made with recombinant humanized type III collagen, demonstrating improved endothelialization and reduced in-stent restenosis in animal models. This innovative coating exhibited anticoagulation and anti-inflammatory properties, positioning it as a promising alternative to traditional drug-eluting stents.

China interventional cardiology devices market is anticipated to hold a considerable CAGR during the forecast period, owing to its large patient population, rapid urbanization, and government-driven healthcare reforms. Local manufacturing capabilities, increased investment in research and development, and growing uptake of minimally invasive procedures are also driving market expansion. In July 2024, MicroPort Scientific Corporation announced that its subsidiary, Shanghai MicroPort Medical, received NMPA approval for Firesorb, the world's first fully bioresorbable cardiac stent. Clinical studies show that Firesorb performs on par with permanent stents, with a 3-year target lesion failure rate of only 3.5% and a thrombosis rate of just 0.32%.

The interventional cardiology devices market in India accounted for a significant market share, owing to the high incidence of cardiac disorders, increasing demand for cost-effective treatment options, and the availability of skilled interventional cardiologists. Rising awareness of early diagnosis and public and private healthcare infrastructure improvements continue to support the country's growing market presence. In September 2022, Wipro GE Healthcare launched its first AI-powered Made in India Cath lab system, Optima IGS 320. Designed for interventional cardiology procedures, the system uses AutoRight technology to optimize imaging and dose parameters in real time, enabling minimally invasive treatments with greater precision.

Latin America Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in Latin America is anticipated to grow at the second fastest CAGR over the forecast period. This is attributable to rising cardiovascular disease prevalence, increasing healthcare investments, and growing adoption of minimally invasive procedures. Efforts to modernize healthcare systems and expand private healthcare facilities are further contributing to market growth across the region.

Brazil interventional cardiology devices market accounted for a significant market share as it benefits from a large patient pool, improving access to advanced cardiac care, and growing government focus on reducing cardiovascular mortality. The presence of skilled healthcare professionals and expanding availability of interventional procedures in both public and private sectors support continued market development. In September 2023, MicroPort Endovastec announced the first clinical use of its Reewarm PTX Drug-Coated Balloon Catheter in Brazil for treating popliteal artery stenosis. The procedure in São Paulo marked the product’s Latin America debut following ANVISA approval in 2022.

Middle East & Africa Interventional Cardiology Devices Market Trends

The interventional cardiology devices market in the MEA holds a significant market share due to a rising burden of lifestyle-related cardiovascular conditions, increasing awareness of interventional therapies, and expanding investments in healthcare infrastructure. Market growth is also supported by ongoing efforts to enhance cardiac care capacity and access in both urban and underserved areas. In May 2024, Bayer and digital health firm Huma launched a cardiovascular risk screening tool in Saudi Arabia, marking the initiative’s first global rollout beyond the U.S.

UAE interventional cardiology devices market holds a significant market share due to its advanced healthcare system, high per capita healthcare spending, and early adoption of cutting-edge medical technologies. Strong government support for healthcare innovation and the country’s positioning as a regional hub for medical tourism further drive demand for interventional cardiology solutions. In September 2024, Translumina expanded its global footprint by launching direct operations in the UAE to strengthen its presence in the fast-growing MENA region. The move enhances access to its cardiovascular devices, including drug-eluting stents developed in collaboration with the German Heart Centre.

Key Interventional Cardiology Devices Company Insights

Key participants in the market focus on devising innovative business growth strategies in product portfolio expansions, partnerships & collaborations, mergers & acquisitions, and business footprint expansions.

Recent Developments

• In May 2025, Boston Scientific announced collaborations with Philips and Siemens to integrate its iLab Ultrasound Imaging System with their interventional X-ray platforms. These integrations aim to enhance intravascular imaging capabilities within cath labs, offering improved workflow and imaging accuracy.

• In September 2024, Uppsala University launched a flexible stent to reduce complications in coronary artery surgery. The Infinity-Swedeheart study, involving 2,400 patients from 20 Swedish hospitals, compared this new stent to the conventional Resolute Onyx stent. This innovation can potentially improve patient recovery and long-term success rates in cardiac surgery.

• In May 2024, Abbott launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India, enhancing treatment options for patients with blocked coronary arteries. This latest generation stent offers improved safety for complex cases and is part of Abbott's ongoing efforts to advance the angioplasty procedure, a minimally invasive method to restore blood flow to the heart using stents.

Interventional Cardiology Devices Market